MCM
IBRX icon

Mazama Capital Management’s ImmunityBio IBRX Stock Holding History

Mazama Capital Management’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-337,404
Closed -$5.85M – 82
2015
Q4 		$5.85M Buy
337,404
+38,989
+13% +$578K 1.08% 28
2015
Q3 		$3.42M Buy
+298,415
New +$6.51M 0.71% 39

Other funds holding IBRX

WCM
Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return
CC
Callan Capital La Jolla, California $1.35B AUM 8.35% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Mazama Capital Management's IBRX Position: Q1 2016 in Review

Mazama Capital Management sold out of ImmunityBio (IBRX) in Q1 2016, closing a stake of 337,404 shares — an estimated $5.85M sold.

Mazama Capital Management first reported a position in IBRX in Q3 2015 and held it in 2 quarters. The position peaked at $5.85M in Q4 2015. 62 funds tracked by Wall St. Rank hold IBRX as of Q1 2016.

  • Mazama Capital Management reported no remaining ImmunityBio position as of Q1 2016 after selling out during the quarter.
  • Mazama Capital Management sold 337,404 ImmunityBio shares in Q1 2016, an estimated $5.85M.
  • Mazama Capital Management first reported a position in ImmunityBio in Q3 2015 and held it in 2 quarters.
  • Mazama Capital Management's ImmunityBio position peaked at $5.85M in Q4 2015.
  • 62 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2016.

Based on Mazama Capital Management's 13F filing for Q1 2016.